NMPA vs FDA: Navigating China's Medical Device Registration

China is the world's second-largest medical device market, and its regulatory pathway has grown significantly more sophisticated over the past decade. For foreign manufacturers, entering China requires registering with the National Medical Products Administration (NMPA) — a process that differs from FDA clearance in fundamental ways, including language requirements, in-country testing obligations, and the role of the local agent known as the Marketing Authorization Holder (MAH).

This article provides a practical comparison of the NMPA and FDA pathways, covering classification, review bodies, clinical trial requirements, timelines, and the key challenges foreign manufacturers encounter when seeking China registration.

Regulatory Bodies: NMPA and CMDE

NMPA (formerly CFDA — China Food and Drug Administration) is China's central competent authority for drugs, medical devices, and cosmetics. Within NMPA's structure, the technical review of medical device registration applications is conducted by the Center for Medical Device Evaluation (CMDE), which functions similarly to FDA's CDRH in terms of scientific review.

Provincial and local Drug Regulatory Bureaus handle Class I device filings and play a role in facility inspections, but Class II and Class III device registrations are centrally managed at the national level by NMPA/CMDE.

The FDA equivalent — CDRH — similarly serves as both the scientific reviewer and regulatory decision-maker for devices in the U.S. Both organizations have invested heavily in review capacity and have published performance goals, though NMPA's review timelines are often less predictable than FDA's MDUFA-governed targets.

Classification System

China: Three-Class System China uses a risk-based classification system with three classes:

• Class I: Low risk. Filed with local regulatory bureaus. Most basic, low-risk devices fall here.
• Class II: Moderate risk. Requires national NMPA registration. Most diagnostic, therapeutic, and monitoring devices fall here. CMDE conducts the technical review.
• Class III: High risk. Requires national NMPA registration with the most rigorous technical review. Implantable devices, devices that sustain or support life, and devices that present potential serious risks belong here.

FDA: Three-Class System with Pathway Differentiation The FDA also uses a three-class system (Class I/II/III), but the key differentiator is the submission pathway rather than the reviewing body. As covered in our FDA vs EMA comparison, the 510(k), De Novo, and PMA pathways each have distinct clinical and technical evidence requirements. Both China and the U.S. apply stricter scrutiny to higher-risk devices, but how that scrutiny manifests differs considerably.

The CMDE Review Process

For Class II and Class III devices, the NMPA registration process follows a structured sequence:

1. Technical File Preparation: The application must include product overview, design verification and validation reports, biocompatibility data, labeling, instructions for use (IFU), and clinical evaluation.
2. Registration in NMPA's Online System: The Chinese agent (MAH holder) submits the dossier electronically via NMPA's registration platform.
3. Formal Acceptance Review: CMDE checks completeness and issues a formal acceptance decision within 5 working days.
4. Technical Review: CMDE reviewers assess the technical dossier. For Class III devices, this involves detailed review by multiple technical experts, often resulting in questions (deficiency letters) that require manufacturer responses.
5. On-Site Inspection: For Class III devices and some Class II devices with clinical data, NMPA may conduct a manufacturing facility inspection (domestic or international).
6. Registration Certificate Issuance: Upon successful review, NMPA issues a registration certificate valid for 5 years.

Key difference from FDA: The FDA's 510(k) review is almost entirely documentary — manufacturing inspections occur separately through the Quality System Regulation/device QSR framework. NMPA frequently ties facility inspections directly to the registration approval process.

Clinical Trial Requirements in China

This is one of the most consequential differences between NMPA and FDA pathways.

China's clinical trial requirements are defined by product-specific catalogues maintained by NMPA. There are three scenarios:

1. Clinical trial exemption: Products listed on NMPA's exemption catalogue can satisfy clinical requirements through a literature review and/or performance testing alone. This is similar to the FDA's approach for many 510(k) submissions.
2. Clinical literature evaluation: Products not on the exemption list but with substantial published clinical evidence can submit a clinical literature review. However, the evidence must involve the specific device or its substantial equivalent.
3. Mandatory clinical trial in China: High-risk Class III devices and products without sufficient published evidence must conduct a clinical trial within China. This is a critical difference from FDA practice: FDA accepts multinational clinical data; NMPA has historically required or strongly preferred China-specific clinical trial data.

Recent reform: NMPA has progressively expanded acceptance of foreign clinical data for Class III devices under specific conditions, particularly where the foreign clinical trial population is representative of Chinese patients. However, this remains a case-by-case determination, and many Class III devices still require China-specific clinical evidence.

The FDA, by contrast, accepts clinical data from trials conducted outside the United States, provided they meet FDA's standards (21 CFR Part 312, ICH E6 GCP). This makes the U.S. clinical pathway considerably more flexible for manufacturers operating global development programs.

Comparison Table: NMPA vs FDA

Aspect	NMPA (China)	FDA (USA)
Classification	Class I / II / III (risk-based)	Class I / II / III (risk-based)
Technical reviewer	CMDE (for Class II/III)	CDRH
Moderate-risk pathway	NMPA Class II registration	510(k) premarket notification
High-risk pathway	NMPA Class III registration	Premarket Approval (PMA)
Clinical trial flexibility	China-specific data often required	Multinational data accepted
Language requirement	Mandatory Chinese documentation	English
Local representative	MAH holder required (Chinese entity)	U.S. Agent (foreign manufacturer)
Typical timeline (Class II)	12–24 months	6–12 months (510(k))
Typical timeline (Class III)	24–48 months	18–36 months (PMA)
Registration certificate validity	5 years	Indefinite (subject to continuous compliance)
Facility inspection	Tied to registration approval	Separate QSR inspection program
UDI requirement	Yes — NMPA UDI system	Yes — FDA GUDID

Chinese Language Requirements

All NMPA registration dossiers must be submitted in Mandarin Chinese. This is a non-negotiable requirement with significant practical implications:

• Product labeling, instructions for use, and clinical manuals must be in Chinese.
• Technical reports, clinical evaluation reports, and biocompatibility summaries must be translated and culturally adapted — not just linguistically translated. Terminology must match NMPA's own regulatory vocabulary.
• Responses to CMDE deficiency letters must be drafted in Chinese and must be submitted through the Chinese MAH holder.

The quality of translation is scrutinized. Poor translations increase the risk of deficiency letters, delays, and application rejection. Many manufacturers work with specialized regulatory affairs firms based in China to ensure documentation meets CMDE standards.

In-Country Testing Requirements

For many device categories, NMPA requires that performance testing — including electrical safety, electromagnetic compatibility (EMC), and specific device performance tests — be conducted in NMPA-recognized Chinese laboratories. This is distinct from FDA practice, which accepts testing from any ISO 17025-accredited laboratory globally.

The requirement for in-country testing adds cost and time to the China registration process, particularly for manufacturers who have already conducted testing for FDA or CE submissions. While NMPA has made some efforts to recognize foreign test data (particularly from IECEE CB scheme participants), many device categories still require dedicated China testing.

MAH Holder Requirements

Foreign manufacturers cannot register medical devices in China independently. They must appoint a Marketing Authorization Holder (MAH) — a Chinese legal entity that holds the registration certificate and bears regulatory responsibility for the product in China.

The MAH holder can be:

• A Chinese subsidiary of the foreign manufacturer
• An independent Chinese distributor authorized to act as MAH
• A specialized regulatory affairs company acting as MAH

The MAH holder is responsible for post-market surveillance, adverse event reporting, registration renewal, and responding to NMPA queries. This structure differs from the FDA, where a foreign manufacturer can hold a 510(k) clearance or PMA approval directly, with a U.S. Agent serving as a communication point without bearing full regulatory ownership.

Recent NMPA Reforms

NMPA has undertaken significant regulatory modernization since 2017, including:

• Green channel for innovative devices: A fast-track pathway for genuinely novel devices (similar to FDA Breakthrough Device Designation), offering expedited review timelines.
• Priority review: For devices urgently needed to address public health emergencies or unmet clinical needs.
• Expanded foreign clinical data acceptance: Gradual expansion of circumstances where non-Chinese clinical trial data can satisfy NMPA requirements.
• Harmonization with international standards: Increasing adoption of ISO and IEC standards, reducing some duplicative testing requirements.
• Digital submission platform improvements: Ongoing modernization of NMPA's online dossier submission and review management systems.

These reforms have somewhat reduced the regulatory friction for foreign manufacturers, but China registration remains substantially more complex and time-consuming than FDA 510(k) clearance for most device types.

Key Challenges for Foreign Manufacturers

1. Language barrier: The mandatory Chinese documentation requirement demands skilled regulatory translation, not just linguistic conversion.
2. Mandatory China clinical data: For Class III devices, independent Chinese clinical trials may be unavoidable, adding 2–4 years to market entry timelines.
3. In-country testing: Retesting in NMPA-recognized laboratories duplicates costs already incurred for FDA/CE submissions.
4. MAH complexity: Selecting and managing a Chinese MAH holder adds a layer of contractual, legal, and regulatory complexity.
5. Regulatory change velocity: NMPA releases frequent guidance updates, classification adjustments, and new exemption catalogues. Tracking these changes in real time requires dedicated regulatory monitoring capacity.
6. Post-market obligations: The 5-year certificate renewal cycle and ongoing adverse event reporting obligations require sustained in-China regulatory infrastructure.

Strategic Recommendations

For manufacturers planning a China market entry:

• Classify your device early against NMPA's classification catalogue, not just FDA/EU classification. The same device can fall into different class levels across regulatory systems.
• Assess clinical data requirements before committing to your clinical development strategy. If a China-specific trial is unavoidable, incorporating it into your global clinical program from the start is far more cost-efficient.
• Select your MAH holder carefully. The MAH bears legal responsibility for your product in China. A distributor-MAH arrangement can create conflicts of interest; a subsidiary or specialized regulatory services firm may offer more control.
• Budget for translation and in-country testing as distinct line items in your China regulatory affairs budget.

Conclusion

The NMPA and FDA systems share a common risk-based classification logic, but the practical requirements for China registration — Chinese-language documentation, in-country testing, mandatory local clinical data for many Class III devices, and the MAH holder structure — create a pathway that is genuinely distinct from U.S. or European experience. Manufacturers who treat China as simply "another market" to clear with existing documentation frequently encounter costly surprises.

---

NMPA releases guidance updates, new exemption catalogues, and classification decisions on a rolling basis throughout the year. MedFlux monitors 27 regulators in real time — including NMPA and CMDE — so your regulatory team has immediate visibility into every change that could affect your China registration strategy or product portfolio.